We used a selective inhibitor of APP γ-secretase (ELND006) that was created in order to reduce Aβ formation in Alzheimer's disease (Basi et al., 2010, Probst et al., 2013). The gene discussed is APP; the disease is early-onset autosomal dominant Alzheimer disease.